🔎 Trials Near Me

Beranda › Kanker Rektum › Illinois

Uji klinis Kanker Rektum di Illinois

12 studi untuk Kanker Rektum mencari peserta di lokasi di Illinois.

Kota di Illinois

Teks studi resmi (Bahasa Inggris)

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

  • OSF Saint Anthony's Health Center, Alton
  • Illinois CancerCare-Bloomington, Bloomington
  • Illinois CancerCare-Canton, Canton
  • dan 31 lainnya
Menerima pesertaSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07283939

Family Communications After Genetic Testing

  • OSF Saint Anthony's Health Center, Alton
  • Advocate Outpatient Center - Aurora, Aurora
  • Advocate Good Shepherd Hospital, Barrington
  • dan 46 lainnya
Menerima pesertaSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07143487

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  • Endeavor Health ( Site 2027), Evanston
  • Accellacare of Duly ( Site 2015), Lisle
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06997497

PRE-ISPY Phase I/II Oncology Platform Program

  • The University of Chicago Medicine Comprehensive Cancer Center, Chicago
  • UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox
  • UChicago Medicine Orland Park, Orland Park
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT05868226

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

  • OSF Saint Anthony's Health Center, Alton
  • John H Stroger Jr Hospital of Cook County, Chicago
  • Loyola University Medical Center, Maywood
  • dan 3 lainnya
Menerima peserta
Usia 45 hingga 70 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT05080673

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

  • Rush-Copley Medical Center, Aurora
  • Northwestern University, Chicago
  • Carle at The Riverfront, Danville
  • dan 6 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Jul 2026 · NCT06205485

Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3

  • City of Hope at Illinois Chicago Downtown, Chicago
  • City of Hope at Chicago, Zion
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Jul 2026 · NCT07595874

Integrated Cancer Repository for Cancer Research

  • Rush-Copley Cancer Care Center, Aurora
  • Rush-Copley Healthcare Center, Yorkville
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699

The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer

  • The University of Chicago, Chicago
Menerima peserta
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 15 Jun 2026 · NCT05943210

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

  • Illinois Cancer Specialists, Arlington Heights
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Jun 2026 · NCT07011576

Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

  • Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine University of Chicago Medicine, Chicago
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 hingga 49 · Semua jenis kelamin · Diperbarui 24 Apr 2026 · NCT05732623

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Chicago
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.